First Tracks Biotherapeutics Reports Q2 2026 Financial Results

What Happened

• First Tracks Biotherapeutics, Inc. (TRAX) filed a Current Report on Form 8-K on August 12, 2026 to disclose that it issued a press release announcing its financial results for the three and six months ended June 30, 2026. The press release is attached to the 8-K as Exhibit 99.1.

Key Details

• Filing date: August 12, 2026 (Form 8-K, Item 2.02: Results of Operations and Financial Condition).
• Reporting period: three and six months ended June 30, 2026 (Q2 2026 and year-to-date).
• Press release attached as Exhibit 99.1 to the 8-K (dated August 12, 2026).
• Report signed on behalf of the company by Ajim Tamboli, Chief Financial Officer.

Why It Matters

• This 8-K signals that First Tracks has released its latest quarterly financial results (earnings/revenue/quarterly results). Investors should review the attached press release for the detailed numbers (revenue, net income/loss, cash position, and any management commentary or guidance).
• The 8-K itself does not present the financial figures in-line; the press release (Exhibit 99.1) contains the substantive details needed to assess the company’s recent operating and financial condition.